Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Pharmaceuticals Regulatory News (HEMO)

Share Price Information for Hemogenyx Pharmaceuticals (HEMO)

Share Price is delayed by 15 minutes
Get Live Data
760.00    -8.50 (-1.11%)
Bid:
733.00
Ask:
775.00
Spread: 42.00 (5.73%)
Market Cap: £51.68m
HEMO Live PriceLast checked at - London Stock Exchange

Intraday Hemogenyx Pharmaceuticals Share Chart

Holding(s) in Company

25 Nov 2015 11:56

RNS Number : 9401G
Silver Falcon PLC
25 November 2015
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

SILVER FALCON PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Abdelatif LACHAB

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

25/11/2015

6. Date on which issuer notified:

25/11/2015

7. Threshold(s) that is/are crossed orreached: vi, vii

4%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

2,300,000

2,300,000

2,600,000

2,600,000

4%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

2,600,000

4%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Abdelatif Lachab

15. Contact telephone number:

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLPGGAAGUPAGGA
Date   Source Headline
5th Jun 20267:00 amRNSNotice of AGM
29th May 20269:18 amRNSGrant of Options and Extension of Warrant Term
30th Apr 20264:04 pmRNSFinal Results
28th Apr 20267:00 amRNSInstitutional Fundraise
14th Apr 20267:00 amRNSAnnual IND Report with FDA
31st Mar 20261:22 pmRNSTech Transfer Completion and Clinical Trial Update
27th Feb 20268:10 amRNSTotal Voting Rights
24th Feb 20267:00 amRNSHolding(s) in Company
23rd Feb 20267:00 amRNSExercise of Warrants and Issue of Equity
10th Feb 20263:52 pmRNSIssue of Equity - Correction
10th Feb 20267:00 amRNSIssue of Equity
30th Jan 20267:00 amRNSTotal Voting Rights
12th Jan 20267:00 amRNSHolding(s) in Company
22nd Dec 20258:00 amRNSUpdate on Admission of Shares
18th Dec 20257:00 amRNSIssue of Equity
8th Dec 202512:48 pmRNSHolding(s) in Company
28th Nov 20257:00 amRNSTotal Voting Rights
19th Nov 202511:47 amRNSPublication of Prospectus
29th Oct 20257:00 amRNSClinical Trial Update and Grant of Share Awards
6th Oct 20257:00 amRNSClearance to Initiate Pediatric Enrolment
30th Sep 20257:00 amRNSHalf-year Report
30th Sep 20257:00 amRNSTotal Voting Rights
23rd Sep 20257:00 amRNSHemogenyx Signs Letter of Intent
18th Sep 20251:16 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSThird Patient Safety
11th Sep 20257:00 amRNS-RInvitation to Participate at DCNY Summit
8th Sep 20257:00 amRNSManufacturing Partnership with Made Scientific
5th Sep 20257:00 amRNSExercise of Warrants and Issue of Equity
3rd Sep 20251:57 pmRNSExercise of Warrants and Issue of Equity
1st Sep 20253:06 pmRNSIssue of convertible loan notes
29th Aug 20257:00 amRNSResult of Audit Tender
26th Aug 202511:44 amRNSHemogenyx raises £570,000 and Director's Dealing
15th Aug 20257:00 amRNSThird Patient Treated with HG-CT-1 CAR-T Therapy
31st Jul 20257:00 amRNSTotal Voting Rights
29th Jul 20258:00 amRNSPlacing to Raise £250,000 and Director’s Dealing
16th Jul 20257:00 amRNSHemogenyx Awarded Grant
30th Jun 20257:00 amRNSTotal Voting Rights
17th Jun 20257:00 amRNSClearance to Proceed with Pediatric Expansion
3rd Jun 20252:02 pmRNSPlacing to Raise £451,250 and Director’s Dealing
3rd Jun 20257:00 amRNSSecond Patient Passes Initial Safety Tests
30th May 20253:14 pmRNSTotal Voting Rights
29th May 20252:06 pmRNSResult of AGM
14th May 20257:00 amRNS-RPediatric Amendment to Clinical Protocol
13th May 20257:00 amRNSAGM Correction
8th May 20257:00 amRNSPlacing to Raise £451,250 and Director’s Dealing
2nd May 20254:24 pmRNSNotice of AGM
2nd May 20257:00 amRNSSecond Patient Treated with HG-CT-1 CAR-T Therapy
28th Apr 20257:00 amRNSFinal Results
3rd Apr 20257:00 amRNS-RFDA Annual Report
31st Mar 20257:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.